Janux Therapeutics (JANX) Accumulated Expenses (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Accumulated Expenses data on file, last reported at $2.2 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 83.15% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $2.2 million, a 83.15% decrease from a year earlier, with the FY2025 full-year figure at $4.6 million, down 60.72% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $2.2 million, down from $4.6 million in the prior quarter.
• Over the last five years, Accumulated Expenses for JANX reached as high as $16.0 million in Q2 2025 and fell as low as $1.4 million in Q1 2023.
• Historically, Accumulated Expenses has averaged $6.8 million across 5 years, with a median of $5.8 million in 2024.
• Across the five-year window, Accumulated Expenses jumped 823.47% in 2022 and tumbled 83.15% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $8.2 million in 2022, then sank by 59.62% to $3.3 million in 2023, then surged by 253.74% to $11.7 million in 2024, then sank by 60.72% to $4.6 million in 2025, then plunged by 51.02% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $2.2 million in Q1 2026, $4.6 million in Q4 2025, and $4.0 million in Q3 2025.